Study of ARO-ANG3 in Adults With Mixed Dyslipidemia
Public ClinicalTrials.gov record NCT04832971. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double-blind, Placebo-controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-ANG3 in Adults With Mixed Dyslipidemia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of AROANG3-2001 is to evaluate the efficacy and safety of ARO-ANG3 in participants with mixed dyslipidemia. Participants will initially receive 2 subcutaneous injections of ARO-ANG3 or placebo. Participants who complete the double-blind treatment period may opt to continue in an open-label extension during which they will receive up to 8 doses of ARO-ANG3.
Study identification
- NCT ID
- NCT04832971
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 204 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 27, 2021
- Primary completion
- Aug 29, 2022
- Completion
- Sep 24, 2024
- Last update posted
- Dec 2, 2025
2021 – 2024
United States locations
- U.S. sites
- 13
- U.S. states
- 10
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site 5 | Huntington Park | California | 90255 | — |
| Research Site 7 | Hialeah | Florida | 33012 | — |
| Research Site 17 | Miami | Florida | 33144 | — |
| Research Site 8 | Port Orange | Florida | 32127 | — |
| Research Site 24 | Minneapolis | Minnesota | 55455 | — |
| Research Site 10 | Omaha | Nebraska | 68114 | — |
| Research Site 23 | Las Vegas | Nevada | 89121 | — |
| Research Site 22 | New York | New York | 10029 | — |
| Research Site 15 | Greensboro | North Carolina | 27408 | — |
| Research Site 2 | Morehead City | North Carolina | 28557 | — |
| Research Site 1 | Marion | Ohio | 43302 | — |
| Research Site 4 | Camp Hill | Pennsylvania | 17011 | — |
| Research Site 11 | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04832971, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 2, 2025 · Synced Sep 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04832971 live on ClinicalTrials.gov.